{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:56:58Z","timestamp":1773273418696,"version":"3.50.1"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"11","funder":[{"name":"Gladstone Center for AIDS Research","award":["P30A1027763 to S.\u00a0M.-L.]"],"award-info":[{"award-number":["P30A1027763 to S.\u00a0M.-L.]"]}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01AI132128"],"award-info":[{"award-number":["1R01AI132128"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R56AI116342"],"award-info":[{"award-number":["R56AI116342"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R33AI116218"],"award-info":[{"award-number":["R33AI116218"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R56AI091573"],"award-info":[{"award-number":["R56AI091573"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19AI096109"],"award-info":[{"award-number":["U19AI096109"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["1R01DK108349"],"award-info":[{"award-number":["1R01DK108349"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["1R01DK120387"],"award-info":[{"award-number":["1R01DK120387"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","award":["IK2 CX000520"],"award-info":[{"award-number":["IK2 CX000520"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","award":["I01 BX000192"],"award-info":[{"award-number":["I01 BX000192"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"name":"American Foundation for AIDS Research Institute for HIV Cure Research","award":["109301"],"award-info":[{"award-number":["109301"]}]},{"name":"American Foundation for AIDS Research Institute for HIV Cure Research","award":["PID2019-109870RB-I00"],"award-info":[{"award-number":["PID2019-109870RB-I00"]}]},{"DOI":"10.13039\/501100004837","name":"Spanish Ministry of Science and Innovation","doi-asserted-by":"publisher","award":["RETIC RD16\/0025\/0041"],"award-info":[{"award-number":["RETIC RD16\/0025\/0041"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Regional Development Fund\/European Social Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Antiretroviral therapy (ART) intensification and disruption of latency have been suggested as strategies to eradicate HIV. ABX464 is a novel antiviral that inhibits HIV RNA biogenesis. We investigated its effect on HIV transcription and total and intact HIV DNA in CD4+ T cells from ART-suppressed participants enrolled in the ABIVAX-005 clinical trial (NCT02990325).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Peripheral CD4+ T cells were available for analysis from 9 ART-suppressed participants who were treated daily with 150 mg of ABX464 for 4 weeks. Total and intact HIV DNA and initiated, 5\u2019elongated, unspliced, polyadenylated, and multiply-spliced HIV transcripts were quantified at weeks 0, 4, and 8 using ddPCR.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We observed a significant decrease in total HIV DNA (P\u2005=\u2005.008, median fold change (mfc)\u2005=\u20050.8) and a lower median level of intact HIV DNA (P\u2005=\u2005not significant [n.s.], mfc\u2005=\u20050.8) after ABX464 treatment. Moreover, we observed a decrease in initiated HIV RNA per million CD4+ T cells and per provirus (P\u2005=\u2005.05, mfc\u2005=\u20050.7; P\u2005=\u2005.004, mfc\u2005=\u20050.5, respectively), a trend toward a decrease in the 5\u2019elongated HIV RNA per provirus (P\u2005=\u2005.07, mfc\u2005=\u20050.5), and a lower median level of unspliced HIV RNA (P\u2005=\u2005n.s., mfc\u2005=\u20050.6), but no decrease in polyadenylated or multiply-spliced HIV RNA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this substudy, ABX464 had a dual effect of decreasing total HIV DNA (and possibly intact proviruses) and HIV transcription per provirus. To further characterize its specific mechanism of action, long-term administration of ABX464 should be studied in a larger cohort.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>NCT02990325.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciab733","type":"journal-article","created":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T13:40:56Z","timestamp":1629985256000},"page":"2044-2049","source":"Crossref","is-referenced-by-count":12,"title":["ABX464 Decreases the Total Human Immunodeficiency Virus (HIV) Reservoir and HIV Transcription Initiation in CD4+ T Cells From Antiretroviral Therapy\u2013Suppressed Individuals Living With HIV"],"prefix":"10.1093","volume":"74","author":[{"given":"Sara","family":"Moron-Lopez","sequence":"first","affiliation":[{"name":"Department of Medicine, San Francisco Veterans Affairs Medical Center , San Francisco, California , USA"},{"name":"Department of Medicine, University of California\u2013San Francisco , San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Bernal","sequence":"additional","affiliation":[{"name":"IrsiCaixa AIDS Research Institute , Badalona , Spain"},{"name":"University of Vic-Central University of Catalonia , Vic , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph K","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Medicine, San Francisco Veterans Affairs Medical Center , San Francisco, California , USA"},{"name":"Department of Medicine, University of California\u2013San Francisco , San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Martinez-Picado","sequence":"additional","affiliation":[{"name":"IrsiCaixa AIDS Research Institute , Badalona , Spain"},{"name":"University of Vic-Central University of Catalonia , Vic , Spain"},{"name":"Catalan Institution for Research and Advanced Studies , Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven A","family":"Yukl","sequence":"additional","affiliation":[{"name":"Department of Medicine, San Francisco Veterans Affairs Medical Center , San Francisco, California , USA"},{"name":"Department of Medicine, University of California\u2013San Francisco , San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,8,26]]},"reference":[{"key":"2022061019021224800_CIT0001","doi-asserted-by":"crossref","first-page":"13193","DOI":"10.1073\/pnas.94.24.13193","article-title":"Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy","volume":"94","author":"Chun","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061019021224800_CIT0002","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1126\/science.278.5341.1291","article-title":"Recovery of replication-competent HIV despite prolonged suppression of plasma viremia","volume":"278","author":"Wong","year":"1997","journal-title":"Science"},{"key":"2022061019021224800_CIT0003","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","article-title":"Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy","volume":"278","author":"Finzi","year":"1997","journal-title":"Science"},{"key":"2022061019021224800_CIT0004","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41598-018-37813-y","article-title":"Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing","volume":"9","author":"Vautrin","year":"2019","journal-title":"Sci Rep"},{"key":"2022061019021224800_CIT0005","article-title":"Durable control of viral rebound in humanized mice by ABX464 targeting rev functions","author":"Tazi","year":"2015"},{"key":"2022061019021224800_CIT0006","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S2055-6640(20)30273-9","article-title":"Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1: a phase IIa randomised controlled study","volume":"5","author":"Rutsaert","year":"2019","journal-title":"J Virus Erad"},{"key":"2022061019021224800_CIT0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S2055-6640(20)30566-5","article-title":"Oral ABX464 reduces the HIV DNA reservoir in CD4+ peripheral blood T cells","volume":"3","author":"Steens","year":"2017","journal-title":"J Virus Eradicat"},{"key":"2022061019021224800_CIT0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aap9927","article-title":"HIV latency in isolated patient CD4+T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing","volume":"10","author":"Yukl","year":"2018","journal-title":"Sci Transl Med"},{"key":"2022061019021224800_CIT0009","doi-asserted-by":"crossref","first-page":"e0175899","DOI":"10.1371\/journal.pone.0175899","article-title":"Sensitive quantification of the HIV-1 reservoir in gut-associated lymphoid tissue","volume":"12","author":"Mor\u00f3n-L\u00f3pez","year":"2017","journal-title":"PLoS One"},{"key":"2022061019021224800_CIT0010","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-019-0898-8","article-title":"A quantitative approach for measuring the reservoir of latent HIV-1 proviruses","volume":"566","author":"Bruner","year":"2019","journal-title":"Nature"},{"key":"2022061019021224800_CIT0011","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/cr.2013.116","article-title":"MicroRNA-124 mediates the cholinergic anti-inflammatory action through inhibiting the production of pro-inflammatory cytokines","volume":"23","author":"Sun","year":"2013","journal-title":"Cell Res"},{"key":"2022061019021224800_CIT0012","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1471-2164-6-75","article-title":"Control of gene expression during T cell activation: alternate regulation of mRNA transcription and mRNA stability","volume":"6","author":"Cheadle","year":"2005","journal-title":"BMC Genomics"},{"key":"2022061019021224800_CIT0013","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1093\/infdis\/jiv521","article-title":"Short-term treatment with interferon alfa diminishes expression of HIV-1 and reduces CD4 + T-cell activation in patients coinfected with HIV and hepatitis C virus and receiving antiretroviral therapy","volume":"213","author":"Mor\u00f3n-L\u00f3pez","year":"2015","journal-title":"J Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciab733\/40861703\/ciab733.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/74\/11\/2044\/44019156\/ciab733.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/74\/11\/2044\/44019156\/ciab733.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T19:05:17Z","timestamp":1654887917000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/74\/11\/2044\/6357882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,26]]},"references-count":13,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,8,26]]},"published-print":{"date-parts":[[2022,6,10]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciab733","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2021,8,26]]}}}